Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance

Indivior Pharmaceuticals, Inc.

2026-Q1 EPS reported $0.69 revenue$317,000,000

Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).
SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.
Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.
Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.
Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Indivior Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $317 million, net income $89 million, EPS $0.69 diluted earnings per share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $317 million
Net income: $89 million
EPS: $0.69 diluted earnings per share
Guidance: raised
Result: reported results

Exact text from the filing

Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance • Q1’26 Total Net Revenue of $317 Million, Up 19% YoY • Q1’26 Total SUBLOCADE ® Net Revenue of $232 Million, Up 32% YoY • Q1’26 GAAP Net Income of $89 Million and Q1’26 Non-GAAP Net Income of $123 Million • Record

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-193925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.